Metallothionein-Mediated Antioxidant Defense System and Its Response to Exercise Training Are Impaired in Human Type 2 Diabetes
- Celena Scheede-Bergdahl1,
- Milena Penkowa2,
- Juan Hidalgo3,
- David B. Olsen1,
- Peter Schjerling4,
- Clara Prats1,
- Robert Boushel5 and
- Flemming Dela1
- 1Copenhagen Muscle Research Center, The Panum Institute, Department of Medical Physiology, University of Copenhagen, Copenhagen, Denmark
- 2Centre of Inflammation and Metabolism, Department of Medical Anatomy at the Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
- 3Institute of Neurosciences and Department of Cellular Biology, Physiology and Immunology, Animal Physiology Unit, Faculty of Sciences, Autonomous University of Barcelona, Barcelona, Spain
- 4Copenhagen Muscle Research Centre, Department of Molecular Muscle Biology, Rigshospitalet, Copenhagen, Denmark
- 5Department of Exercise Science, Concordia University, Montréal, Canada
- Address correspondence and reprint requests to Celena Scheede-Bergdahl, The Copenhagen Muscle Research Centre, The Panum Institute, Department of Medical Physiology, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark. E-mail: celena{at}mfi.ku.dk
Abstract
Oxidative stress is implicated in diabetes complications, during which endogenous antioxidant defenses have important pathophysiological consequences. To date, the significance of endogenous antioxidants such as metallothioneins I and II (MT-I+II) in type 2 diabetes remains unclear. To examine the MT-I+II–mediated antioxidant capacity and its response to exercise training in the skeletal muscle of patients with type 2 diabetes, biopsies and blood samples were taken from 13 matched subjects (type 2 diabetes n = 8, control subjects n = 5) both before and after 8 weeks of exercise training. Immunohistochemical analysis revealed reduced MT-I+II levels in the skeletal muscle of type 2 diabetic subjects compared with control subjects. Control subjects produced a robust increase of MT-I+II in response to training; however, in type 2 diabetes, MT-I+II levels remained essentially unchanged. Significantly lower levels of MT-I+II were also detected in the plasma of type 2 diabetic subjects compared with control subjects. These results suggest that, in control subjects, the MT-I+II defense system is active and inducible within skeletal muscle tissue and plasma. In type 2 diabetes, reduced levels of MT-I+II in muscle and plasma, as well as the deficient MT-I+II response to exercise, indicate that this antioxidant defense is impaired. This study presents a novel candidate in the pathogenesis of complications related to oxidative stress in type 2 diabetes.
- GSH, glutathione
- MDA, malondialdehyde
- MT-I+II, metallothioneins I and II
- NITT, nitrotyrosine
- ROS, reactive oxygen species
- SOD, superoxide dismutase
Footnotes
-
- Accepted August 12, 2005.
- Received October 4, 2004.
- DIABETES














